THE ROLE OF BOARD MEMBERS

  • Board members are entrepreneurial executives with extensive experience in asset management, startups/SMEs and global corporations

  • Board controls investment, budget, nomination, compensation, audit, and guarantees alignment of interests

  • Board is regulated by an organization charter

  • Board operates its own internal processes and procedures based on EVCA professional standards

THE ROLE OF BOARD MEMBERS

  • Board members are entrepreneurial executives with extensive experience in asset management, startups/SMEs and global corporations

  • Board controls investment, budget, nomination, compensation, audit, and guarantees alignment of interests

  • Board is regulated by an organization charter

  • Board operates its own internal processes and procedures based on EVCA professional standards

remora.png
  • Home

  • Our Team

  • Primary Focus

  • Assets

  • News

  • Contact us

  • More

    • All Posts
    • REMORA
    • ACTIVEN
    • ATLAB
    • AVALUN
    • BEPATIENT
    • CYTUNE
    • FASTOX
    • IVO
    • OGD2
    Search
    Remora Capital
    • Feb 15
    • 2 min

    Czech Republic Grants National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product

    70
    Remora Capital
    • Dec 15, 2020
    • 2 min

    Telix Pharma Files New Drug Submission with Health Canada for Prostate Cancer Imaging...

    00
    Remora Capital
    • Dec 1, 2020
    • 1 min

    Telix Pharma Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product

    12
    Remora Capital
    • Dec 1, 2020
    • 2 min

    Telix Receives Approval for First-In-Human Study of Next Generation Prostate Cancer Therapy Product

    40
    Remora Capital
    • Nov 23, 2020
    • 2 min

    Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA

    40
    Remora Capital
    • Nov 1, 2020
    • 4 min

    Telix and China Grand Pharma Announce Strategic Licence for Greater China market

    00
    Remora Capital
    • Jul 8, 2020
    • 3 min

    Telix Pharmaceuticals and ReleXion Announce Strategic Collaboration

    10
    Remora Capital
    • Jul 7, 2020
    • 2 min

    Telix Receives FDA Feedback on Phase 3 Trial Design for Prostate Cancer Therapy Product

    1250
    Remora Capital
    • Apr 7, 2020
    • 2 min

    Telix Pharmaceuticals Enters Commercial Distribution Agreement for Prostate Cancer Diagnostic

    00
    Remora Capital
    • Jan 8, 2020
    • 3 min

    TELIX: Acceleration of Prostate Cancer Therapy Program

    330
    Remora Capital
    • Dec 26, 2019
    • 1 min

    TELIX: NDA Clinical Briefing Package Submitted to the US FDA

    Melbourne (Australia) – 27th December 2019. Telix Pharmaceuticals Limited (ASX: TLX), is pleased to announce that it has submitted a comp...

    150
    Remora Capital
    • Oct 13, 2019
    • 2 min

    Telix Pharmaceuticals and GE Healthcare : Maximising 68Ga Supply for Prostate Cancer Imaging

    Melbourne (Australia) – 14 October 2019. Telix Pharmaceuticals Limited (ASX:TLX, “Telix”, the “Company”) a clinical-stage biopharmaceutic...

    120
    Remora Capital
    • Aug 27, 2019
    • 4 min

    TELIX: FDA Pre-NDA Meeting Outcomes : TLX591-CDx (illumet ™)

    TLX591-CDx (68Ga-PSMA) for the imaging of prostate cancer with positron emission tomography (PET).

    1150
    Remora Capital
    • Jul 22, 2019
    • 4 min

    Telix Pharmaceuticals Reports Positive Consultation for European Approval of Prostate Imaging Agent

    Program relevance: TLX591-CDx (68Ga-PSMA-11) for the imaging of metastatic prostate cancer with positron emission tomography (PET) Synops...

    130
    Remora Capital
    • May 31, 2019
    • 3 min

    Telix Pharmaceuticals and Emory Winship Cancer Institute to Collaborate on Clinical Trial

    Program relevance: TLX591-CDx (68Ga-PSMA) for the imaging of prostate cancer with positron emission tomography (PET). Branded as illumetT...

    60
    Remora Capital
    • May 29, 2019
    • 3 min

    TELIX: Prostate Imaging Program (illumetTM) : Commercial and Regulatory Update

    TLX591-CDx (68Ga-PSMA) for the imaging of prostate cancer with positron emission tomography (PET). Branded as illumetTM in the US market.

    160
    Remora Capital
    • Apr 24, 2019
    • 3 min

    TELIX: Fractionated Prostate Cancer Therapy Data Published, Significant Treatment Benefit

    Date: 26th April, 2019 Program relevance: TLX591 (Prostate Therapy), TLX591-CDx (Prostate Imaging) Synopsis: The development of TLX591 is...

    100
    Remora Capital
    • Jan 24, 2019
    • 5 min

    Telix Group Expands Prostate Imaging Capability through ININ Technology Partnership

    90
    Remora Capital
    • Jan 8, 2019
    • 6 min

    TELIX: Strategy Update – Acceleration of Prostate Cancer Therapy Program

    Program relevance: TLX591 Synopsis: In conjunction with the completion of the acquisition of Atlab Pharma SAS (ASX release: 11/09/18) Tel...

    120
    Remora Capital
    • Sep 12, 2018
    • 5 min

    Telix Pharmaceuticals Completes Acquisition of Atlab Pharma

    Melbourne (Australia) and Nantes (France) – 11 September 2018. Telix Pharmaceuticals Limited (“Telix”, the “Company”) today announced the...

    730
    Legal Disclaimer
    • LinkedIn Social Icon